期刊文献+

自体CIK细胞治疗恶性肿瘤免疫表型和杀伤活性变化 被引量:5

Difference of immune phenotypes and NK cell activity after treatment of autologous CIK cell on malignant tumor
原文传递
导出
摘要 目的观察自体CIK细胞治疗恶性肿瘤前后免疫袁型和杀伤活性变化。方法采用流式细胞术检测50例肿瘤患者CIK细胞治疗前、后免疫表型的变化,采用3H—TdR释放法检测杀伤活性的变化。结果CIK治疗后,CD3^+、CD4^+细胞百分率上升,CD8^+细胞百分率下调,CD4^+/CD8^+比值上升,CD19细胞百分率下降,与治疗前比较差异有统计学意义(P〈0.05),但CD3^+、CD4^+、CD8^+细胞绝对值未达到健康者水平(P〉0.05)。治疗后NK细胞百分率明显升高(P〈0.05),达到健康者水平(P〉0.05)。在杀伤活性的研究中,与CIK细胞治疗前(19±6)%相比,治疗后杀伤活性百分率(22±5)%明显升高,达17.5%(P〈0.01),但未达到健康者水平(P〈0.05)。结论自体CIK细胞治疗能明显提高肿瘤患者细胞免疫功能。 Objective To investigate the difference of immune phenotypes and NK cell activity after treatment of autologous CIK cell on malignant tumor. Methods In the 50 patients with malignant tumor infused with CIK cell, the differences of immune phenotypes and activity of NK cells were respcetitively measured using FACS and 3H - TdR release assay. Results Compared with pre - treatment of autologous CIK cell, CD3^+ and CD4^+ expression percentage rise were up -regulated significantly, CD8^+ cell expression percentage rise decline; The CD4^+/CD8^+ ratio rise, CD19 cell expression percentage rise decline, the comparison has signifieanct difference ( P 〈 0.05 ). After treatment of autologous CIK cell CD3^- CD56^+ cell expression percentage increase remarkablely. In the study of NK activity, NK activity ( 22 ± 5 ) % , was higher obviously than pre - treatment ( 19 ± 6 ) %. Conclusions Treatment ofautologous CIK cell can enhance recent immunity function of the tumor patients obviously.
出处 《中国实用医刊》 2009年第24期1-3,共3页 Chinese Journal of Practical Medicine
基金 江苏省苏州科技局基金项目(SS0524)
关键词 CIK细胞 免疫表型 杀伤活性 流式细胞术 3H—TdR释放法 CIK cell Immune phenotypes NK activities FACS 3H -TdR release assay
  • 相关文献

同被引文献44

  • 1聂鑫,刘侃峰,滕少侠.CIK治疗恶性肿瘤的研究进展及临床应用现状[J].中国实用医药,2007,2(7):106-108. 被引量:13
  • 2杨光,刘长安,贾廷珍.γ射线照射对脐血淋巴细胞增殖和NK细胞活性的影响[J].中华放射医学与防护杂志,2006,26(1):6-9. 被引量:5
  • 3贾廷珍,刘长安,杨光,严智昌,陈旭芳,李惠平,马力文,张淑兰,王保中.脐血基础与临床研究[J].中华放射医学与防护杂志,2006,26(1):10-14. 被引量:7
  • 4柳子川,祁岩超,杨波,萧石燕.CIK治疗后肿瘤病人外周血淋巴细胞绝对数值变化的研究[J].世界肿瘤杂志,2007,6(1):14-16. 被引量:2
  • 5Olioso P,Giancola R,Di Riti M,et al.Immunotherapy with cytokine induced killer cells in solid and hematopoietic tumours:a pilot clinical trial.Hematol Oncol,2009,27(33):130-139.
  • 6Leemhuis T,Wells S,Scheffold C,et al.A phase Ⅰ trial of autologous cytokine-induced killer cells for the treatment of relapsed Hodgkin disease and non-Hodgkin lymphoma.Biol Blood Marrow Transplant,2005,11(33):181-187.
  • 7Schmidt-Wolf IG,Lefterova P,Mehta BA,et al.Phenotypic characterization and identification of effector cells involved in tumor cell recognition of cytokine-induced killer cella.Exp Hematol,1993,21(13):1673-1679.
  • 8Margolin KA,Negrin RS,Forman SJ,et al.Cellular immunotherapy and autologous transp1antation for hematologic malignancy[J].Immunol Rev,1997,157:231-240.
  • 9Verneris MR,Karami M,Baker J,et al.Role of NK-G2D signaling in the cytotoxicity of activated and expanded CD8+ T cells[J].Blood,2004,103(8):3065-3072.
  • 10Hoffman WH, Biade S, Zilfou JT, et al. Transcriptional repression of the anti-apoptotie survivin gene by wild type p53 [J]. J Biol Chem,2002,277(5):3247 -3257.

引证文献5

二级引证文献12

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部